Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Regulatory | 4 | 2026 | 221 | 1.890 |
Why?
|
| Kidney Transplantation | 3 | 2026 | 325 | 0.920 |
Why?
|
| Transplantation Tolerance | 2 | 2022 | 69 | 0.740 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 247 | 0.660 |
Why?
|
| Histocompatibility, Maternal-Fetal | 1 | 2018 | 1 | 0.580 |
Why?
|
| B7-H1 Antigen | 2 | 2015 | 60 | 0.450 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2015 | 64 | 0.450 |
Why?
|
| Immune Tolerance | 2 | 2018 | 183 | 0.440 |
Why?
|
| Th17 Cells | 1 | 2015 | 63 | 0.430 |
Why?
|
| Fetus | 1 | 2015 | 103 | 0.420 |
Why?
|
| Rectal Neoplasms | 2 | 2026 | 139 | 0.410 |
Why?
|
| Biomarkers, Tumor | 2 | 2026 | 526 | 0.360 |
Why?
|
| Heart Transplantation | 2 | 2019 | 180 | 0.260 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2016 | 22 | 0.250 |
Why?
|
| Retinal Dehydrogenase | 1 | 2026 | 6 | 0.240 |
Why?
|
| Fetal Proteins | 1 | 2026 | 10 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2026 | 7 | 0.240 |
Why?
|
| Transplant Recipients | 1 | 2026 | 32 | 0.230 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2026 | 24 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2026 | 61 | 0.230 |
Why?
|
| Single-Cell Analysis | 1 | 2026 | 117 | 0.220 |
Why?
|
| Antigens, CD | 1 | 2026 | 342 | 0.220 |
Why?
|
| Gene Expression Profiling | 2 | 2026 | 796 | 0.210 |
Why?
|
| Flow Cytometry | 1 | 2026 | 663 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2026 | 344 | 0.200 |
Why?
|
| Organ Transplantation | 1 | 2024 | 46 | 0.200 |
Why?
|
| Biomarkers | 2 | 2019 | 1481 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 104 | 0.190 |
Why?
|
| Adenosine Triphosphate | 2 | 2022 | 301 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 354 | 0.180 |
Why?
|
| Transcriptome | 1 | 2026 | 399 | 0.180 |
Why?
|
| Isoantigens | 1 | 2022 | 72 | 0.180 |
Why?
|
| Phenotype | 1 | 2026 | 1233 | 0.180 |
Why?
|
| Cell Line | 1 | 2026 | 2024 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2019 | 234 | 0.170 |
Why?
|
| Glucuronidase | 1 | 2021 | 25 | 0.170 |
Why?
|
| Humans | 14 | 2026 | 65463 | 0.160 |
Why?
|
| Antibodies | 1 | 2021 | 187 | 0.160 |
Why?
|
| Alternative Splicing | 1 | 2021 | 138 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 178 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 132 | 0.150 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2018 | 9 | 0.150 |
Why?
|
| Rituximab | 1 | 2019 | 89 | 0.140 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2018 | 32 | 0.140 |
Why?
|
| Models, Immunological | 1 | 2018 | 85 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 215 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2019 | 83 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2019 | 110 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1039 | 0.130 |
Why?
|
| Female | 8 | 2026 | 34193 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 220 | 0.130 |
Why?
|
| Glycolysis | 1 | 2016 | 59 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2018 | 531 | 0.120 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2015 | 49 | 0.110 |
Why?
|
| Imidazoles | 1 | 2015 | 82 | 0.110 |
Why?
|
| Toll-Like Receptors | 1 | 2016 | 434 | 0.110 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2015 | 104 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 218 | 0.100 |
Why?
|
| Neoplasms | 1 | 2024 | 1372 | 0.100 |
Why?
|
| Macrophages | 1 | 2018 | 1038 | 0.100 |
Why?
|
| Animals | 4 | 2022 | 21381 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 1334 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2016 | 3155 | 0.090 |
Why?
|
| Pregnancy | 1 | 2018 | 2390 | 0.090 |
Why?
|
| Prognosis | 2 | 2026 | 1789 | 0.080 |
Why?
|
| Heart Failure | 1 | 2019 | 962 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2026 | 6929 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 449 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 630 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 1567 | 0.070 |
Why?
|
| Middle Aged | 5 | 2026 | 18387 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2024 | 1008 | 0.060 |
Why?
|
| Activated-Leukocyte Cell Adhesion Molecule | 1 | 2026 | 2 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2026 | 130 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 2 | 2016 | 235 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2026 | 1114 | 0.050 |
Why?
|
| Aged | 3 | 2026 | 15052 | 0.050 |
Why?
|
| Male | 4 | 2026 | 31187 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 3324 | 0.040 |
Why?
|
| Apoptosis | 2 | 2016 | 1098 | 0.040 |
Why?
|
| Adult | 3 | 2026 | 17461 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 47 | 0.040 |
Why?
|
| Vimentin | 1 | 2019 | 19 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2019 | 21 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2019 | 61 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 140 | 0.030 |
Why?
|
| Risk | 1 | 2019 | 374 | 0.030 |
Why?
|
| Immune System | 1 | 2019 | 132 | 0.030 |
Why?
|
| Myosins | 1 | 2019 | 118 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 743 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2016 | 24 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 744 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2016 | 28 | 0.030 |
Why?
|
| Pancreatitis, Chronic | 1 | 2016 | 21 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 50 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 233 | 0.030 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2016 | 219 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 381 | 0.030 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2016 | 207 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 611 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 167 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 350 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 145 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 289 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2492 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 526 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2014 | 274 | 0.020 |
Why?
|
| Mice | 2 | 2015 | 11138 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 734 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4837 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 5806 | 0.020 |
Why?
|